nach oben

Pediatric Drugs

Erschienen in:

23.08.2023 | Leading Article

The Future of Advanced Therapies for Pediatric Crohn’s Disease

verfasst von: Julie Gallagher, Joel R. Rosh, Benjamin Sahn

Erschienen in: Pediatric Drugs | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Pediatric Crohn’s disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule therapies, which have become available for adult patients since anti-tumor necrosis factor medications, is paramount for tighter disease control for a large proportion of children. Newer advanced therapies such as anti-integrin and anti-interleukin biologics, and several small-molecule agents capitalize on various mechanisms through narrower immunologic targets and reduced immunogenicity. Given limited regulatory approvals of these agents for use in children with Crohn’s disease, clinicians continue to rely on data extrapolated from clinical trials in adult patients, sparse pediatric studies, and a growing real-world experience for treatment selection and optimization. In this article, we discuss currently available treatment options, pipeline drugs, and relevant data as they pertain to some of the most pressing clinical challenges faced in treating pediatric Crohn’s disease.

Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16(6):953–61. https://doi.org/10.1002/ibd.21152.CrossRefPubMed

Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL, ECCO-EpiCom. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014;8(11):1351–61. https://doi.org/10.1016/j.crohns.2014.05.006.CrossRefPubMed

Kurowski JA, Milinovich A, Ji X, et al. Differences in biologic utilization and surgery rates in pediatric and adult Crohn’s disease: results from a large electronic medical record-derived cohort. Inflamm Bowel Dis. 2021;27(7):1035–44. https://doi.org/10.1093/ibd/izaa239.CrossRefPubMed

Ahmed S, Alam S, Alsabri M. Health-related quality of life in pediatric inflammatory bowel disease patients: a narrative review. Cureus. 2022;14(9): e29282. https://doi.org/10.7759/cureus.29282.CrossRefPubMedPubMedCentral

Sahn B, Markowitz J. The natural history of Crohn disease in children. In: Mamula P, Grossman A, Baldassano R, Kelsen J, Markowitz J, editors. Pediatric inflammatory bowel disease. Cham: Springer; 2017.

Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–89. https://doi.org/10.1016/S0140-6736(17)32641-7.CrossRefPubMed

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83. https://doi.org/10.1053/j.gastro.2020.12.031.CrossRefPubMed

Payen E, Neuraz A, Zenzeri L, et al. Adalimumab therapy in pediatric Crohn disease: a 2-year follow-up comparing “top-down” and “step-up” strategies. J Pediatr Gastroenterol Nutr. 2023;76(2):166–73. https://doi.org/10.1097/MPG.0000000000003643.CrossRefPubMed

Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27(3):651–62. https://doi.org/10.1185/03007995.2010.547575.CrossRefPubMed

10.

Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2022;71(1):34–42. https://doi.org/10.1136/gutjnl-2020-322339.CrossRefPubMed

11.

Colman RJ, Lawton RC, Dubinsky MC, Rubin DT. Methotrexate for the treatment of pediatric Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2018;24(10):2135–41. https://doi.org/10.1093/ibd/izy078.CrossRefPubMedPubMedCentral

12.

Rosh JR. The current role of methotrexate in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2020;16(1):43–6.PubMed

13.

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. https://doi.org/10.1056/NEJMoa0904492.CrossRefPubMed

14.

Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;10(10): CD000545. https://doi.org/10.1002/14651858.CD000545.pub5.CrossRefPubMed

15.

Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57(12):1639–41. https://doi.org/10.1136/gut.2008.163279.CrossRefPubMed

16.

Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8): 1901–14.e3. https://doi.org/10.1053/j.gastro.2017.02.004.CrossRef

17.

Spencer EA, Dubinsky MC. Precision medicine in pediatric inflammatory bowel disease. Pediatr Clin North Am. 2021;68(6):1171–90. https://doi.org/10.1016/j.pcl.2021.07.011.CrossRefPubMed

18.

Hyams JS, Turner D, Cohen SA, et al. Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or Crohn’s disease: results from the phase 2 HUBBLE Study. J Crohns Colitis. 2022;16(8):1243–54. https://doi.org/10.1093/ecco-jcc/jjac036.CrossRefPubMedPubMedCentral

19.

Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol. 2023;8(1):31–42. https://doi.org/10.1016/S2468-1253(22)00307-7.CrossRefPubMed

20.

Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022;20(5): 1059–67.e9. https://doi.org/10.1016/j.cgh.2021.09.028.CrossRef

21.

Sandborn WJ, Panes J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(1):43–55. https://doi.org/10.1016/S2468-1253(22)00303-X.CrossRefPubMed

22.

Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7. https://doi.org/10.1097/MPG.0000000000002362.CrossRefPubMedPubMedCentral

23.

Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022;20(3): 578–90.e4. https://doi.org/10.1016/j.cgh.2021.02.025.CrossRef

24.

Rosh JR, Turner D, Griffiths A, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931–42. https://doi.org/10.1093/ecco-jcc/jjab089.CrossRefPubMedPubMedCentral

25.

Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol. 2009;104(12):3042–9. https://doi.org/10.1038/ajg.2009.493.CrossRefPubMed

26.

Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–11. https://doi.org/10.1016/S0140-6736(22)00688-2.CrossRefPubMed

27.

Danese S, Vermeire S, D’Haens G, et al. Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294–306. https://doi.org/10.1016/S2468-1253(21)00474-X.CrossRefPubMed

28.

Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the Speed-up Study): a multicenter study from the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717–23. https://doi.org/10.1097/MPG.0000000000003608.CrossRefPubMed

29.

Bermejo F, Jimenez L, Algaba A, et al. Re-induction with intravenous ustekinumab in patients with Crohn’s disease and a loss of response to this therapy. Inflamm Bowel Dis. 2022;28(1):41–7. https://doi.org/10.1093/ibd/izab015.CrossRefPubMed

30.

Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56(1):53–8. https://doi.org/10.1080/00365521.2020.1854848.CrossRefPubMed

31.

Ruemmele FM, Rosh J, Faubion WA, et al. Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn’s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12(10):1249–54. https://doi.org/10.1093/ecco-jcc/jjy087.CrossRefPubMedPubMedCentral

32.

Papamichael K, VandeCasteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn’s disease: an ACCENT-II post hoc analysis. Am J Gastroenterol. 2021;116(5):1007–14. https://doi.org/10.14309/ajg.0000000000001111.CrossRefPubMedPubMedCentral

33.

D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–30. https://doi.org/10.1016/S0140-6736(22)00467-6.CrossRefPubMed

34.

Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–46. https://doi.org/10.1016/S0140-6736(22)00466-4.CrossRefPubMed

35.

Fumery M, Defrance A, Roblin X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study. Aliment Pharmacol Ther. 2023;57(4):426–34. https://doi.org/10.1111/apt.17358.CrossRefPubMed

36.

Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2022;162(2):495–508. https://doi.org/10.1053/j.gastro.2021.10.050.CrossRefPubMed

37.

Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 Study. Gastroenterology. 2022;162(6): 1650–64.e8. https://doi.org/10.1053/j.gastro.2022.01.047.CrossRef

38.

Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049–59. https://doi.org/10.1136/gutjnl-2016-312735.CrossRefPubMed

39.

Lee SD, Singla A, Harper J, et al. Tofacitinib appears well tolerated and effective for the treatment of patients with refractory Crohn’s disease. Dig Dis Sci. 2022;67(8):4043–8. https://doi.org/10.1007/s10620-022-07444-5.CrossRefPubMed

40.

Fenster M, Alayo QA, Khatiwada A, et al. Real-world effectiveness and safety of tofacitinib in Crohn’s disease and IBD-U: a multicenter study from the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021;19(10): 2207–9.e3. https://doi.org/10.1016/j.cgh.2020.10.025.CrossRef

41.

Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn’s disease. Inflamm Bowel Dis. 2023;29(7):1175–6. https://doi.org/10.1093/ibd/izad048.CrossRefPubMed

42.

Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8): 2123–38.e8. https://doi.org/10.1053/j.gastro.2020.01.047.CrossRef

43.

D’Haens G, Panes J, Louis E, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST Extension Study. Clin Gastroenterol Hepatol. 2022;20(10): 2337–46.e3. https://doi.org/10.1016/j.cgh.2021.12.030.CrossRef

44.

Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–80. https://doi.org/10.1056/NEJMoa2212728.CrossRefPubMed

45.

Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–84. https://doi.org/10.1016/S0140-6736(21)00666-8.CrossRefPubMed

46.

Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–75. https://doi.org/10.1016/S0140-6736(16)32537-5.CrossRefPubMed

47.

D’Haens GR, Lee S, Taylor SA, et al. Filgotinib for the treatment of small bowel Crohn’s disease: the DIVERGENCE 1 Trial. Gastroenterology. 2023;165(1): 289–92.e3. https://doi.org/10.1053/j.gastro.2023.03.234.CrossRef

48.

Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):819–28. https://doi.org/10.1016/S2468-1253(20)30188-6.CrossRefPubMed

49.

Feagan BG, Schreiber S, Afzali A, et al. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn’s disease: the YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022;122: 106958. https://doi.org/10.1016/j.cct.2022.106958.CrossRefPubMedPubMedCentral

50.

Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–6. https://doi.org/10.1097/MIB.0000000000000865.CrossRefPubMed

51.

Vermeire S, D’Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn’s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16(1):27–38. https://doi.org/10.1093/ecco-jcc/jjab133.CrossRefPubMed

52.

Dulai PS, Amiot A, Peyrin-Biroulet L, et al. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2020;51(5):553–64. https://doi.org/10.1111/apt.15609.CrossRefPubMed

53.

Park J, Chun J, Yoon H, Cheon JH. Feasibility of a clinical dDecision support tool for ustekinumab to predict clinical remission and relapse in patients with Crohn’s disease: a multicenter observational study. Inflamm Bowel Dis. 2023;29(4):548–54. https://doi.org/10.1093/ibd/izac105.CrossRefPubMed

54.

Ananthakrishnan AN, Luo C, Yajnik V, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017;21(5): 603–10.e3. https://doi.org/10.1016/j.chom.2017.04.010.CrossRef

55.

Doherty MK, Ding T, Koumpouras C, et al. Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn’s disease patients. MBio. 2018;9(2): e02120–17. https://doi.org/10.1128/mBio.02120-17.CrossRefPubMedPubMedCentral

56.

Winter DA, Joosse ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr. 2020;70(6):763–76. https://doi.org/10.1097/MPG.0000000000002631.CrossRefPubMed

57.

Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748–56. https://doi.org/10.1016/j.cgh.2015.04.010.CrossRefPubMed

58.

Kappelman MD, Wohl DA, Herfarth HH, et al. Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn’s disease: a peagmatic randomized yrial. Gastroenterology. 2023;165(1): 149–61.e7. https://doi.org/10.1053/j.gastro.2023.03.224.CrossRef

59.

Plevris N, Lyons M, Jenkinson PW, et al. Higher adalimumab drug levels during maintenance therapy for Crohn’s disease are associated with biologic remission. Inflamm Bowel Dis. 2019;25(6):1036–43. https://doi.org/10.1093/ibd/izy320.CrossRefPubMed

60.

Wilson A, Choi B, Sey M, Ponich T, Beaton M, Kim RB. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study. BMC Gastroenterol. 2021;21(1):77. https://doi.org/10.1186/s12876-021-01650-7.CrossRefPubMedPubMedCentral

61.

Assa A, Dorfman L, Shouval DS, Shamir R, Cohen S. Therapeutic drug monitoring-guided high-dose infliximab for infantile-onset inflammatory bowel disease: a case series. J Pediatr Gastroenterol Nutr. 2020;71(4):516–20. https://doi.org/10.1097/MPG.0000000000002832.CrossRefPubMed

62.

Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179(12):1935–44. https://doi.org/10.1007/s00431-020-03750-0.CrossRefPubMedPubMedCentral

63.

Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12): 1937–46.e8. https://doi.org/10.1016/j.cgh.2018.04.040.CrossRef

64.

Hanzel J, Zdovc J, Kurent T, et al. Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn’s disease likely to achieve endoscopic and biochemical remission. Clin Gastroenterol Hepatol. 2021;19(1): 111–8.e10. https://doi.org/10.1016/j.cgh.2020.02.033.CrossRef

65.

Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in Crohn’s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13(7):864–72. https://doi.org/10.1093/ecco-jcc/jjz008.CrossRefPubMed

66.

Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3): e361–79. https://doi.org/10.1016/j.cgh.2021.03.034.CrossRef

67.

Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;51(11):1031–8. https://doi.org/10.1111/apt.15719.CrossRefPubMedPubMedCentral

68.

Kwapisz L, Raffals LE, Bruining DH, et al. Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center. Clin Gastroenterol Hepatol. 2021;19(3):616–7. https://doi.org/10.1016/j.cgh.2020.02.017.CrossRefPubMed

69.

Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(8):1210–4. https://doi.org/10.1093/ibd/izaa277.CrossRefPubMed

70.

Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Kierkus J. Dual biologic therapy in moderate to severe pediatric inflammatory Bbwel disease: a retrospective study. Children (Basel). 2022;10(1):11. https://doi.org/10.3390/children10010011.CrossRefPubMed

71.

Howard G, Weiner D, Bar-Or I, Levine A. Dual biologic therapy with vedolizumab and ustekinumab for refractory Crohn’s disease in children. Eur J Gastroenterol Hepatol. 2022;34(4):372–4. https://doi.org/10.1097/MEG.0000000000002203.CrossRefPubMed

72.

Lightner AL, Otero-Pineiro A, Reese J, et al. A phase I study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of pediatric perianal fistulizing Crohn’s disease. Inflamm Bowel Dis. 2023. https://doi.org/10.1093/ibd/izad100.CrossRefPubMed

73.

Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn’s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65(5):713–20. https://doi.org/10.1097/DCR.0000000000002325.CrossRefPubMedPubMedCentral

74.

Carvello M, Lightner A, Yamamoto T, Kotze PG, Spinelli A. Mesenchymal stem cells for perianal Crohn’s disease. Cells. 2019;8(7):764. https://doi.org/10.3390/cells8070764.CrossRefPubMedPubMedCentral

75.

Vieujean S, Loly JP, Boutaffala L, et al. Mesenchymal stem cell injection in Crohn’s disease strictures: a phase I–II clinical study. J Crohns Colitis. 2022;16(3):506–10. https://doi.org/10.1093/ecco-jcc/jjab154.CrossRefPubMed

76.

Dulai PS, Gleeson MW, Taylor D, Holubar SD, Buckey JC, Siegel CA. Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(11):1266–75. https://doi.org/10.1111/apt.12753.CrossRefPubMed

77.

Hasan B, Yim Y, Ur Rashid M, et al. Hyperbaric oxygen therapy in chronic inflammatory conditions of the pouch. Inflamm Bowel Dis. 2021;27(7):965–70. https://doi.org/10.1093/ibd/izaa245.CrossRefPubMed

78.

Kante B, Sahu P, Kedia S, et al. Efficacy and tolerability of hyperbaric oxygen therapy in small bowel stricturing Crohn’s disease: a pilot study. Intest Res. 2022;20(2):231–9. https://doi.org/10.5217/ir.2021.00056.CrossRefPubMedPubMedCentral

79.

Lansdorp CA, Gecse KB, Buskens CJ, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease. Aliment Pharmacol Ther. 2021;53(5):587–97. https://doi.org/10.1111/apt.16228.CrossRefPubMed

80.

Lansdorp CA, Buskens CJ, Gecse KB, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease: results of the HOT-TOPIC trial after 1-year follow-up. United Eur Gastroenterol J. 2022;10(2):160–8. https://doi.org/10.1002/ueg2.12189.CrossRef

81.

Lansdorp CA, Buskens CJ, Gecse KB, D’Haens G, van Hulst RA. Hyperbaric oxygen therapy for the treatment of rectovaginal fistulas in patients with Crohn’s disease: results of the HOT-REVA pilot study. BJS Open. 2021;5(3): zrab042. https://doi.org/10.1093/bjsopen/zrab042.CrossRefPubMedPubMedCentral

82.

Green MS, Purohi M, Sadacharam K, Mychaskiw G. Efficacy of hyperbaric oxygen in patients with Crohn’s disease: two case reports. Undersea Hyperb Med. 2013;40(2):201–4.PubMed

83.

Sharma Y, Bousvaros A, Liu E, Bender SJ. Natural history of children with mild Crohn’s disease. World J Gastroenterol. 2019;25(30):4235–45. https://doi.org/10.3748/wjg.v25.i30.4235.CrossRefPubMedPubMedCentral

84.

SigallBoneh R, Van Limbergen J, Wine E, et al. Dietary therapies induce rapid response and remission in pediatric patients with active Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(4):752–9. https://doi.org/10.1016/j.cgh.2020.04.006.CrossRef

85.

Sohouli MH, Fatahi S, Farahmand F, Alimadadi H, Seraj SS, Rohani P. Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2022;56(3):384–95. https://doi.org/10.1111/apt.17109.CrossRefPubMed

86.

Cuomo M, Carobbio A, Aloi M, et al. Induction of remission with exclusive enteral nutrition in children with Crohn’s disease: determinants of higher adherence and response. Inflamm Bowel Dis. 2022. https://doi.org/10.1093/ibd/izac215.CrossRef

87.

Lee D, Baldassano RN, Otley AR, et al. Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn’s disease. Inflamm Bowel Dis. 2015;21(8):1786–93. https://doi.org/10.1097/MIB.0000000000000426.CrossRefPubMed

88.

Chen JM, He LW, Yan T, et al. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease. Gastroenterol Rep (Oxf). 2019;7(3):176–84. https://doi.org/10.1093/gastro/goy050.CrossRefPubMed

89.

Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2): 440–50.e8. https://doi.org/10.1053/j.gastro.2019.04.021.CrossRef

90.

Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014;59(4):516–21. https://doi.org/10.1097/MPG.0000000000000449.CrossRefPubMed

91.

Suskind DL, Lee D, Kim YM, et al. The specific carbohydrate diet and diet modification as induction therapy for pediatric Crohn’s disease: a randomized diet controlled trial. Nutrients. 2020;12(12):3749. https://doi.org/10.3390/nu12123749.CrossRefPubMedPubMedCentral

92.

Lewis JD, Sandler RS, Brotherton C, et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s disease. Gastroenterology. 2021;161(3): 837–52.e9. https://doi.org/10.1053/j.gastro.2021.05.047.CrossRef

93.

Pavlov VA, Chavan SS, Tracey KJ. Bioelectronic medicine: from preclinical studies on the inflammatory reflex to new approaches in disease diagnosis and treatment. Cold Spring Harb Perspect Med. 2020;10(3): a034140. https://doi.org/10.1101/cshperspect.a034140.CrossRefPubMedPubMedCentral

94.

Sinniger V, Pellissier S, Fauvelle F, et al. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease. Neurogastroenterol Motil. 2020;32(10): e13911. https://doi.org/10.1111/nmo.13911.CrossRefPubMed

95.

Sahn B, Lu Y, Hui-Yuen JS, et al. The safety of COVID-19 vaccination in immunocompromised children and young adults with immune-mediated inflammatory disease. Acta Paediatr. 2022;112(4):794–881. https://doi.org/10.1111/apa.16652.CrossRef

96.

Turner D, Griffiths AM, Wilson D, et al. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020;69(1):32–41. https://doi.org/10.1136/gutjnl-2018-317987.CrossRefPubMed

Titel: The Future of Advanced Therapies for Pediatric Crohn’s Disease
verfasst von: Julie Gallagher
Joel R. Rosh
Benjamin Sahn
Publikationsdatum: 23.08.2023
Verlag: Springer International Publishing
Erschienen in: Pediatric Drugs / Ausgabe 6/2023
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-023-00590-x

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The Future of Advanced Therapies for Pediatric Crohn’s Disease

Abstract

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab

Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit

Correction to: Viloxazine: Pediatric First Approval

Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants

Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie